The 11 most recent market catalysts affecting $BLTE, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 55
Mizuho Maintains Outperform on Belite Bio, Raises Price Target to $234
Mizuho analyst Graig Suvannavejh maintained an 'Outperform' rating on Belite Bio and raised the price target from $220 to $234. This action signals continued bullish sentiment from…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 60
HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $245
HC Wainwright & Co. analyst Yi Chen has maintained a 'Buy' rating on Belite Bio (BLTE) and raised the price target from $214 to $245. This action signals increased confidence from …
Sep 4, 2026
Corporate Catalyst
Bullish
Impact 75
Belite Bio shares are trading higher after Canaccord Genuity initiated coverage on the stock with a Buy rating and announced a $303 price target.
This headline represents a significant corporate catalyst for Belite Bio. Analyst initiations, especially with a 'Buy' rating and a high price target, often lead to immediate posit…
Sep 4, 2026
Corporate Catalyst
Neutral
Impact 75
Canaccord Genuity Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $303
Canaccord Genuity's initiation of coverage on Belite Bio with a 'Buy' rating and a $303 price target is a significant positive catalyst for the company. Analyst coverage, especiall…
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 55
Cantor Fitzgerald Maintains Overweight on Belite Bio, Raises Price Target to $270
Cantor Fitzgerald analyst Steve Seedhouse has updated their outlook on Belite Bio, raising the price target from $266 to $270 and reaffirming an Overweight rating. This action sign…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 92
Belite Bio Q2 Adj. EPS $(0.54) Beats $(0.79) Estimate
Belite Bio (BLTE) announced Q2 adjusted EPS of $(0.54), which was a substantial beat against the consensus estimate of $(0.79). This positive surprise indicates better-than-expecte…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $214
HC Wainwright & Co. analyst Yi Chen maintained a 'Buy' rating on Belite Bio and raised the price target from $200 to $214. This action signals increased analyst confidence in Belit…
Aug 11, 2026
Corporate Catalyst
Neutral
Impact 95
Belite Bio Announces FDA Acceptance And Priority Review Of Tinlarebant NDA For Stargardt Disease Type 1, With PDUFA Date Of February 12, 2027
The FDA's acceptance and Priority Review of Tinlarebant's NDA is a critical milestone for Belite Bio, significantly de-risking the drug's path to market. Priority Review is granted…
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 75
Why Is Belite Bio Stock Gaining Monday?
Belite Bio released new secondary endpoint statistics from its Phase 3 DRAGON trial for tinlarebant, targeting Stargardt disease type 1 (STGD1). The key finding was a notable diver…
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 85
Belite Bio Announces Additional Secondary Endpoint Data From Phase 3 DRAGON Trial Of Tinlarebant In Stargardt Disease, Presented At ASRS 2026 In Montréal
Belite Bio has reported additional positive secondary endpoint data for its lead therapeutic candidate, tinlarebant, in treating Stargardt disease. The key finding is that quantita…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.